Celebrating India’s independence, enterprise and progress
news

Artelus wins Roche Drishti HealthTech Challenge

Jun 26, 2026 · Source: cision
Artelus wins Roche Drishti HealthTech Challenge
  • Drishti HealthTech Challenge is a joint initiative by DPIIT and Roche Pharma India under the Startup India program
  • 80+ startups submitted their applications
  • Artelus will receive a financial grant of INR 35 lakhs to co-develop and pilot its winning solution

NEW DELHI, June 26, 2026 -- Leading healthcare startup 'Artelus' - an AI-based provider of healthtech solutions, aiming to enhance diagnosis and treatment for improved patient outcomes was recognised as the winner of Startup India's Drishti HealthTech Challenge, a joint initiative by the Department for Promotion of Industry and Internal Trade (DPIIT) and Roche Pharma India. This recognition is a testimony to the rapid progress made by homegrown health tech startups who are disrupting India's healthcare landscape. 

Aimed at identifying and supporting healthtech startups in India to develop transformative, scalable solutions for some of the country's most important health challenges, the Drishti HealthTech Challenge received high-impact applications from 80+ startups working in the areas of digital health.

The Jury comprising of retinal health experts, startup mentors and select members of the Roche India leadership evaluated the applications through a rigorous, multi-stage evaluation criteria focused on problem relevance, impact potential, market readiness, leadership credibility, and regulatory, legal & IP moats. Artelus emerged as the winner and will receive a financial grant of INR 35 lakhs to co-develop, enhance and pilot its pioneering solution in partnership with Roche Pharma India.

The award ceremony, hosted at the Swiss Embassy in New Delhi in the presence of Her Excellency, Mrs. Maya Tissafi, Ambassador of Switzerland to India and Bhutan, marks another milestone in Indo-Swiss collaboration, driven by Roche's partnership with Startup India and DPIIT to strengthen the healthcare ecosystem in India.

Her Excellency, Mrs. Maya Tissafi, Ambassador of Switzerland to India and Bhutan, said, "The Trade and Economic Partnership Agreement between EFTA and India has intensified the economic relationship between our countries. It creates a ground for exactly the kind of innovation we see today – such as this initiative by Roche Pharma India and Startup India, which creates platforms for entrepreneurs and supports opportunities for collaboration and brings us closer to real-world impact. I would like to offer special congratulations to the winning start-up, Artelus. Its work shows how healthtech can make early diagnosis more accessible and bring quality healthcare closer to those who need it."

Shri Ateesh Kumar Singh, Additional Secretary, DPIIT, said, "Fostering an ecosystem where advanced technology seamlessly integrates with grassroots healthcare delivery is key to sustainable economic development. Initiatives like the Roche Drishti HealthTech Challenge underscore the immense potential of the Indian startup community to deliver high-impact solutions. Startup India, DPIIT remains committed to supporting open innovation frameworks that empower homegrown entrepreneurs to scale their impact across the country."

Roche Pharma India Managing Director & CEO Rajji Mehdwan, said, "Retinal diseases are stealing sight across India. The healthcare community has clinicians dedicated to helping people and the medicines that can truly make a difference. What we didn't have was a way to make early diagnosis accessible to everyone. Artelus solves that. Their offline AI technology brings screening to places we've never been able to reach before—expanding access to a much wider group of people. That changes everything. No patient should lose their vision to something preventable. Our partnership with DPIIT and Startup India reflects Roche's unyielding commitment to India's innovation ecosystem, nurturing local, home-grown solutions for India's unique healthcare challenges." 

About the winning solution

Diabetic Retinopathy (DR) is a rapidly growing public health crisis in India, with delayed diagnosis leading to preventable blindness. The Drishti HealthTech Challenge was launched to uncover scalable, tech-enabled solutions to address this gap.

Artelus's winning innovation—DRISTi (Diabetic Retinopathy Screening)—is an instantaneous, CE Class 1 AI product that completely redefines point-of-care diagnostics. By building a one-of-its-kind 'AI on a Chip,' Artelus enables fully offline retinal screening that functions entirely without internet or cloud connectivity. Alongside their backpack-friendly, 5G-enabled OCT systems, this breakthrough tech democratizes healthcare by bringing comprehensive, transparent retinal diagnostics directly to the remotest corners of India.

Girish Somvanshi, Co-Founder & VP, Artelus, said, "Breakthrough therapies save vision only when patients access treatment in a timely manner. The Roche Drishti Healthtech Challenge recognizes the critical importance of closing that gap. At Artelus, we are building the infrastructure to ensure every patient is identified, referred, treated, and followed up - at a population scale optimized for India and the rest of the world."

About the Roche Drishti HealthTech Challenge

The Drishti HealthTech Challenge, launched on the Startup India platform is a joint initiative by DPIIT and Roche aimed at strengthening India's innovation ecosystem and advancing transformative solutions in healthcare. It invited applications from startups working in the following areas of retinal health:

  • AI driven early screening, referral, and treatment pathways for retinal diseases
  • A unified, interoperable RWE platform that can integrate with existing systems

About Artelus

Artelus is an award-winning Indian healthtech company building innovative AI-powered portable diagnostics, and digital health infrastructure to enable early detection and integrated management of retinal diseases. With a mission to make quality eye care accessible, affordable, and available to populations worldwide, its solutions are deployed across hospitals, public health programs, NGOs, and international markets, helping reduce avoidable blindness at scale.

About Roche Products (India) Pvt. Ltd.

Roche Products (India) Private Limited is as a wholly owned subsidiary of the Roche Group, the world's largest biotech company headquartered in Basel, Switzerland. For 80+ years, Roche has been dedicated to improving lives in India, evolving from Vitamins in the 1940s to advanced, differentiated medicines for cancer, ophthalmology, neurology and blood disorders. For more information, visit www.rocheindia.com

Photo: https://mma.prnewswire.com/media/3001060/Roche_DHTC.jpg

Logo: https://mma.prnewswire.com/media/2937896/5873139/Roche_Logo.jpg

 

Cision View original content to download multimedia:https://www.prnewswire.com/in/news-releases/artelus-wins-roche-drishti-healthtech-challenge-302811738.html

Comments (0)

Login to join the conversation

Login / Register

No comments yet. Be the first to comment!

More to Read

TestMu AI Unveils the Fifth Edition of the TestMu Conference in 2026 news
Aug 14, 2026 1 min

TestMu AI Unveils the Fifth Edition of the TestMu Conference in 2026

The world s largest virtual agentic engineering and quality conference returns with a focus on autonomous quality, agentic workflows, and AI-native testing strategies SAN FRANCISCO and NOIDA, India , Aug. 14, 2026 -- TestMu AI (formerly LambdaTest), the world s first Agentic AI-powered Quality Engineering platform, is excited to unveil the 5th edition of its flagship TestMu Conference, taking place virtually from August 19 21, 2026. This year s event is expected to host over 75,000 developers, builders, and quality engineers from more than 120 countries, making it the world s largest virtual conference dedicated to agentic engineering and quality.

Michael Owen Joins ehamarkets as Global Brand Ambassador news
Aug 14, 2026 1 min

Michael Owen Joins ehamarkets as Global Brand Ambassador

HONG KONG and NEW YORK , Aug. 14, 2026 -- ehamarkets today announced a global brand partnership with England football legend and 2001 Ballon d Or winner Michael Owen, who has joined the brand as its Global Brand Ambassador. Owen said he was drawn to ehamarkets focus on technology, reliability and a simpler trading experience. I m delighted to join ehamarkets as its Global Brand Ambassador. I like the way ehamarkets uses technology to make trading simpler and more efficient. It s exciting to be part of a brand that is building a modern trading experience for people around the world.

RemotePeople Completes 2026 SOC 2 Type II Audit Across Security, Availability, and Confidentiality news
Aug 14, 2026 1 min

RemotePeople Completes 2026 SOC 2 Type II Audit Across Security, Availability, and Confidentiality

The New York-headquartered global Employer of Record renews its SOC 2 Type II attestation for a full 12-month period, adding to its ISO 27001 and GDPR certifications and its recent A+ platform security rating from Astra Security. NEW YORK , Aug. 14, 2026 -- RemotePeople, a global provider of Employer of Record (EOR), payroll, and recruitment services operating in more than 150 countries, today announced the successful completion of its 2026 SOC 2 Type II audit , covering the Security, Availability, and Confidentiality Trust Service Criteria. The independent examination was performed by INTERCERT CPA LLC in accordance with AICPA SSAE 21 attestation standards and covered a continuous 12-month observation period from May 31, 2025 to May 30, 2026.

Bybit TradFi Perpetuals Extend 24/7 Exposure to Over 200 Global Equities and Pre-IPO Assets news
Aug 14, 2026 1 min

Bybit TradFi Perpetuals Extend 24/7 Exposure to Over 200 Global Equities and Pre-IPO Assets

DUBAI, UAE , Aug. 14, 2026 -- Bybit , the world s second-largest cryptocurrency exchange by trading volume, is pleased to announce TradFi Perpetual Contracts now offer over 200 curated TradFi-themed listings , marking one of the highest quality coverage of TradFi derivatives exposure available on a crypto-native platform. The lineup now spans equities, ETFs, precious metals, indices, and oil, with coverage extending across premium US, Hong Kong, South Korean and other equities markets.

Deeper Insights, Better Analytics: Bybit Options Close the Data Gap Between Retail and Institutional Traders news
Aug 14, 2026 1 min

Deeper Insights, Better Analytics: Bybit Options Close the Data Gap Between Retail and Institutional Traders

DUBAI, UAE , Aug. 14, 2026 -- Bybit , the world s second-largest cryptocurrency exchange by trading volume, announced a major upgrade to its Options Data section, introducing a suite of institutional-grade analytics to provide traders with a clearer view of volatility, positioning, and market structure. The redesigned page integrates institutional-grade analytics with a cleaner, more accessible interface for all users. Options trading has been gaining popularity among digital asset derivatives traders, as they increasingly move beyond simple long or short positions to alternative strategies that account for volatility, time decay, and risk management. Options give traders the right, but not the obligation, to buy or sell an asset at a set price before a set date.

Hippocratic AI Unveils Agentic Orchestrators: NYSE Content Update news
Aug 14, 2026 1 min

Hippocratic AI Unveils Agentic Orchestrators: NYSE Content Update

NYSE issues a pre-market daily advisory direct from the trading floor. NEW YORK , Aug. 14, 2026 -- The New York Stock Exchange (NYSE) provides a daily pre-market update directly from the NYSE Trading Floor. Access today s NYSE Pre-market update for market insights before trading begins. Kristen Scholer delivers the pre-market update on August 14th Hippocratic AI says it s announced the next generation of healthcare AI Agentic orchestrators feature teams of conversational voice AI agents focused on delivering outcomes. Co-founder and CEO Munjal Shah will join NYSE Live to take viewers through how the new product works. Renewable energy construction company SunScout to celebrate its dual listing SunScout (NYSE American: SNSC) began trading on NYSE American and NYSE Texas earlier this week. CEO Edwin Cywinski and COO Mark Cywinski will join NYSE Live to discuss the milestone. The S&P 500 will look to build off Thursday s record close. The large-cap index surpassed 7,800 for the first time during Thursday s session. Investors are parsing through July U.S. retail sales data.

Binance Research: Gen Z Leads Net Accumulation Across Every TradFi Product news
Aug 14, 2026 1 min

Binance Research: Gen Z Leads Net Accumulation Across Every TradFi Product

New commentary finds 77% of Gen Z direct-equity accounts are net buyers, with 76% accumulating in bStocks, the highest share of any generation. MUMBAI, India , Aug. 14, 2026 -- Binance Research , the market research arm of the world s largest cryptocurrency exchange Binance , has recently published a new weekly market commentary titled Gen Z Perspective Rewrite . The report examines how Gen Z users behave across three TradFi products, namely, direct equities, bStocks, and TradFi-Perps, and finds behavior that is more disciplined and allocation-oriented than common assumptions suggest.

Bitmine Immersion Technologies Announces Record and Payment Dates for Cash Dividends on 9.50% Series A Perpetual Preferred Stock news
Aug 14, 2026 1 min

Bitmine Immersion Technologies Announces Record and Payment Dates for Cash Dividends on 9.50% Series A Perpetual Preferred Stock

NORWALK, Conn. , Aug. 14, 2026 -- (NYSE: BMNR; BMNP) Bitmine Immersion Technologies, Inc. ( Bitmine or the Company ) announced today that its Board of Directors has declared seventeen cash dividends on the Company s 9.50% Series A Perpetual Preferred Stock (the Series A Preferred Stock ), which is listed on the New York Stock Exchange under the trading symbol BMNP . The dividends will be payable in cash in accordance with the terms of the Certificate of Designations governing the Series A Preferred Stock. The record dates, payment dates, and per-share amounts for each dividend are set forth below: